Breaking Finance News

Zacks Investment Research downgraded ANI Pharmaceuticals Inc (NASDAQ:ANIP) to Hold in a statement released earlier today.

Having a price of $68.96, ANI Pharmaceuticals Inc (NASDAQ:ANIP) traded 1.62% higher on the day. With the last close up 26.67% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. ANIP has recorded a 50-day average of $64.51 and a two hundred day average of $54.44. Trade Volume was up over the average, with 285,675 shares of ANIP changing hands over the typical 219,612

Zacks Investment Research has downgraded ANI Pharmaceuticals Inc (NASDAQ:ANIP) to Hold in a statement released on 10/5/2016.

Recent Performance Chart

ANI Pharmaceuticals Inc (NASDAQ:ANIP)

ANI Pharmaceuticals Inc has PE ratio of 81.03 with a one year low of $26.80 and a one year high of $70.92 and has a market capitalization of $0.

A total of 3 analysts have released a report on ANI Pharmaceuticals Inc. Two analysts rating the company a strong buy, one analyst rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $56.33.

General Company Details For ANI Pharmaceuticals Inc (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company's focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *